Chronic exposure of lung alveolar epithelial type II cells to tobacco-specific carcinogen NNK results in malignant transformation: A new in vitro lung carcinogenesis model

Molecular Carcinogenesis

Volumn 53, Issue 5, 2014, Pages 392-402

  Mennecier, Gregory ^a   Torres, Luciana N ^a   Cogliati, Bruno ^a   Sanches, Daniel S ^a   Mori, Claudia M ^a   Latorre, Andréia O ^a   Chaible, Lucas M ^a   Mackowiak, Ivone I ^a   Nagamine, Marcia K ^a   Da Silva, Tereza C ^a   Fukumasu, Heidge ^a   Dagli, Maria Lucia Zaidan ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hallmarks of transformed cells; In vitro carcinogenesis; Lung cancer; Tobacco specific nitrosamine; Type II pneumocyte

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; CATENIN; CYCLINE; CYTOKERATIN AE1; CYTOKERATIN AE3; F ACTIN; FIBRONECTIN; GELATINASE A; PROTEIN ZO1; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MODEL; CELL CLONE; CELL DISRUPTION; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GROWTH REGULATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INOCULATION; LONG TERM EXPOSURE; LUNG ALVEOLUS EPITHELIUM; LUNG CARCINOGENESIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALIGNANT TRANSFORMATION; MITOSIS INDEX; MORPHOLOGICAL TRAIT; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOBACCO; UNDIFFERENTIATED CARCINOMA;

ANIMALIA; MUS; NICOTIANA TABACUM;

HALLMARKS OF TRANSFORMED CELLS; IN VITRO CARCINOGENESIS; LUNG CANCER; TOBACCO-SPECIFIC NITROSAMINE; TYPE II PNEUMOCYTE;

ANIMALS; BLOTTING, WESTERN; CARCINOGENS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EMBRYO, MAMMALIAN; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NITROSAMINES; PULMONARY ALVEOLI; TOBACCO; WOUND HEALING;

EID: 84898056754     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21987     Document Type: Article

References (47)

1. Hecht SS. Tobacco smoke carcinogens lungcancer. J Natl Cancer Inst 1999; 91:1194-1210.
2. Ochsner A. Corner of history. My first recognition of the relationship of smoking and lung cancer. Prev Med 1973; 2:611-614.
3. Adler I. Primary malignant growths of the lungs and bronchi. New York: Longmans, Green, and Company; 1912.
4. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med 2005; 172:523-529.
5. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2:533-543.
6. IARC. IARC monographs on the evaluation of carcinogenic risks to Humans World Health Organization International Agency for Research on Cancer. Lyon, France: IARC; 2007. Vol. 89.
7. Talhout R, Schulz T, Florek E, van Benthem J, Wester P, Opperhuizen A. Hazardous compounds in tobacco smoke. Int J Environ Res Public Health 2011; 8:613-628.
8. Hecht SS. Smoking and lung cancer-A new role for an old toxicant? Proc Natl Acad Sci USA 2006; 103:15725-15726.
9. Jin Z, Gao F, Flagg T, Deng X. Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation. J Biol Chem 2004; 279:40209-40219.
10. Hoffmann D, Rivenson A, Hecht SS. The biological significance of tobacco-specific N-nitrosamines: Smoking and adenocarcinoma of the lung. Crit Rev Toxicol 1996; 26:199-211.
11. Schrader E, Hirsch-Ernst KI, Richter E, Foth H. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in isolated rat lung and liver. Naunyn Schmiedebergs Arch Pharmacol 1998; 357:336-343.
12. Schrader E, Hirsch-Ernst KI, Scholz E, Kahl GF, Foth H. Metabolism of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in primary cultures of rat alveolar type II cells. Drug Metab Dispos Biol Fate Chem 2000; 28:180-185.
13. Oliveira PA, Colaco A, Chaves R, Guedes-Pinto H, De-La-Cruz PL, Lopes C. Chemical carcinogenesis. Anais da Academia Brasileira de Ciencias 2007; 79:593-616.
14. Zheng HC, Takano Y. NNK-induced lung tumors: A review of animal model. J Oncol 2011; 2011:635379.
15. Belinsky SA, Devereux TR, Foley JF, et al. Role of the alveolar type II cell in the development and progression of pulmonary tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the A/J mouse. Cancer Res 1992; 52:3164-3173.
16. Fukumasu H, Avanzo JL, Sanches DS, Mennecier G, Mori CM, Dagli ML. Higher susceptibility of spontaneous and NNK-induced lung neoplasms in connexin 43 deficient CD1×AJ F1 mice: Paradoxical expression of connexin 43 during lung carcinogenesis. Mol Carcinog 2012; In press
17. Hobson-West Pru. What kind of animal is 'The Three Rs'? Alternat Lab Anim 2009; 37:95-99.
18. Editorial: Reduce, Refine, Replace. The European Union has passed new laws for the protection of laboratory animals according to the 'three Rs' concept. Nat Immun 2010; 11:971.
19. Hecht SS, Carmella SG, Murphy SE, et al. A tobacco-specific lung carcinogen in the urine of men exposed to cigarette smoke. Engl J Med 1993; 18:1543-1546.
20. Besaratinia A, Kleinjans JC, Van Schooten FJ. Biomonitoring of tobacco smoke carcinogenicity by dosimetry of DNA adducts and genotyping and phenotyping of biotransformational enzymes: A review on polycyclic aromatic hydrocarbons. Biomarkers 2002; 7:209-229.
21. Siriwardhana N, Choudhary S, Wang HC. Precancerous model of human breast epithelial cells induced by NNK for prevention. Breast Cancer Res Treat 2008; 109:427-441.
22. Mei J, Hu H, Mcentee M. et al. Transformation of non-cancerous human breast epithelial cell line MCF10A by the tobacco-specific carcinogen NNK. Breast Cancer Res Treat 2003; 79:95-105.
23. Zhao P, Fu J, Yao B, et al. In vitro malignant transformation of human bronchial epithelial cells induced by benzo(a)pyrene. Toxicol In Vitro 2011; 26:362-368.
24. Sambury. et al., ATCC, tech buletin No.8. 2005.
25. Reid YA. Characterization and authentication of cancer cell lines: An overview. Methods Mol Biol 2011; 731:35-43.
26. Kim DK. Estimating doubling time of cells in vitro. In Vitro Cell Dev Biol 1995; 31:419-420.
27. Fukumasu H, Sanches DS, da Silva TC, Ward JM, Dagli ML. Transient disruption of liver gap junctional intercellular communication and induction of apoptosis after administration of 1, 4-bis[2-(3, 5 dichloropyridyloxy)]benzene in mice. Exp Toxicol Pathol 2009; 62:525-531.
28. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001; 410:1111-1116.
29. Smith GB, Bend JR, Bedard LL, Reid KR, Petsikas D, Massey TE. Biotransformation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in peripheral human lung microsomes. Drug Metab Dispos Biol Fate Chem 2003; 31:1134-1141.
30. Akopyan G, Bonavida B. Understanding tobacco smoke carcinogen NNK and lung tumorigenesis. Int J Oncol 2006; 29:745-752.
31. Chen RJ, Chang LW, Lin P, Wang YJ. Epigenetic effects and molecular mechanisms of tumorigenesis induced by cigarette smoke: An overview. J Oncol 2011; In press.
32. Jull BA, Plummer HK, Schuller HM. Nicotinic receptor-mediated activation by the tobacco-specific nitrosamine NNK of a Raf-1/MAP kinase pathway, resulting in phosphorylation of c-myc in human small cell lung carcinoma cells and pulmonary neuroendocrine cells. J Cancer Res Clin Oncol 2001; 127:707-717.
33. West KA, Brognard J, Clark AS, et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003; 111:81-90.
34. Tsurutani J, Castillo SS, Brognard J, et al. Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis 2005; 26:1182-1195.
35. Schuller HM, Plummer HK. Jull BA, III. Receptor-mediated effects of nicotine and its nitrosated derivative NNK on pulmonary neuroendocrine cells. Anat Rec 2003; 270:51-58.
36. Wu WK, Wong HP, Luo SW, et al. 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone from cigarette smoke stimulates colon cancer growth via beta-adrenoceptors. Cancer Res 2005; 65:5277-5277.
37. Gilles C, Polette M, Piette J, et al. High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Cancer 1996; 65:209-213.
38. Hendrix MJ, Seftor EA, Seftor RE, Trevor KT. Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am J Pathol 1997; 150:483-495.
39. Maeda J, Hirano T, Ogiwara A, et al. Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy. Br J Cancer 2008; 98:596-603.
40. Ding Y, Gelfenbeyn K, Freire-de-lima L, Handa K, Hakomori SI. Induction of epithelial-mesenchymal transition with O-glycosylated oncofetal fibronectin. FEBS Lett 2012; 586:1813-1820.
41. Zheng Y, Ritzenthaler JD, Roman J, Han S. Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression. Am J Respir Cell Mol Biol 2007; 37:681-690.
42. Zheng M, Jones DM, Horzempa C, et al. The first type III domain of fibronectin is associated with the expression of cytokines within the lung tumor microenvironment. J Cancer 2011; 2:478-483.
43. Jia D, Yan M, Wang X, et al. Development of a highly metastatic model that reveals a crucial role of fibronectin in lung cancer cell migration and invasion. BMC Cancer 10:364.
44. Malik G, Knowles LM, Dhir R, et al. Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. Cancer Res 70:4327-4334.
45. Rintoul RC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin Sci (Lond) 2002; 102:417-424.
46. Ritzenthaler JD, Han S, Roman J. Stimulation of lung carcinoma cell growth by fibronectin-integrin signalling. Mol Biosyst 2008; 4:1160-1169.
47. Wang W, Chin-Sheng H, Kuo LJ, et al. NNK enhances cell migration through alpha7-nicotinic acetylcholine receptor accompanied by increased of fibronectin expression in gastric cancer. Ann Surg Oncol 2012; In press.